Clinical Research Directory
Browse clinical research sites, groups, and studies.
Propranolol in Primary Progressive Aphasia
Sponsor: University of Missouri-Columbia
Summary
The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.
Official title: Trial of Propranolol in Older Adults with Primary Progressive Aphasia
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-01-13
Completion Date
2027-12
Last Updated
2025-03-28
Healthy Volunteers
No
Conditions
Interventions
Propranolol
Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
Placebo
Placebo will be given on the same schedule as the propranolol regime.
Locations (1)
University of Missouri-Columbia
Columbia, Missouri, United States